Rare Diseases
The AI-Powered Path to Revolutionising Rare Disease Research
February 23 by Joanna EdwardsExplore how AI/ML can accelerate rare disease research and clinical trials, by enhancing inclusivity and efficiency, to deliver new drugs and therapeutics to patients. With insights from Dr. Harsha Ra...
AI in Pharma: Navigating New Frontiers in Drug Discovery and Development
February 23 by Joanna EdwardsBringing a new drug to market typically takes a decade or more and approximately US$2.5 billion. However, new technology, including AI, can dramatically shorten the drug discovery process and reduce t...
Gene silencing: A potential new treatment for rare disease
June 28 by Giles CampionWe look at the latest development in precision medicine: gene silencing
Orphan Drugs – Reinventing Economies of Scale
November 16 by Cristina FalcãoEconomies of scale come in many flavors. Including the oddity flavor where the number of manufactured products decreases and the size of markets shrink. Orphan drugs are economies of scale’...
Are Orphan Drugs Still a Licence to Print Money?
July 20 by Andrea CharlesIn this podcast Donald Macarthur, global pharmaceutical business analyst, speaks to Andrea Charles from Pharma IQ, about Pharma's steps into the orphan drug market and whether payers can afford to fun...
Renewed Realisation of Orphan Drug Market Potential
December 08 by Pharma IQOrphan drugs were previously considered not worthwhile for development by pharmaceutical companies due to their small patient base, which was translated by some to mean small revenues. Orphan buz...